WASHINGTON TRUST Co Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

WASHINGTON TRUST Co lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,768 shares of the company's stock after selling 1,872 shares during the period. WASHINGTON TRUST Co's holdings in Johnson & Johnson were worth $20,526,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Tallon Kerry Patrick acquired a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $290,000. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the last quarter. West Michigan Advisors LLC lifted its position in shares of Johnson & Johnson by 12.9% in the 4th quarter. West Michigan Advisors LLC now owns 4,458 shares of the company's stock worth $645,000 after purchasing an additional 509 shares during the period. Finally, Metis Global Partners LLC boosted its stake in shares of Johnson & Johnson by 1.4% in the 4th quarter. Metis Global Partners LLC now owns 140,714 shares of the company's stock valued at $20,350,000 after purchasing an additional 1,956 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ traded up $0.63 during mid-day trading on Thursday, reaching $156.19. 1,446,381 shares of the company's stock traded hands, compared to its average volume of 8,020,342. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The business has a 50-day simple moving average of $153.63 and a 200 day simple moving average of $153.88. The stock has a market cap of $375.80 billion, a P/E ratio of 17.37, a PEG ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.